Aurinia Pharmaceuticals Inc. (AUPH)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 5.12 |
| Open | 5.15 |
| Bid | 5.13 x 600 |
| Ask | 5.16 x 300 |
| Day's range | 5.04 - 5.20 |
| 52-week range | 4.71 - 12.43 |
| Volume | |
| Avg. volume | 2,145,632 |
| Market cap | 736.548M |
| Beta (5Y monthly) | 1.38 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
ROCKVILLE, Md. & EDMONTON, Alberta, May 07, 2024--Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
- Business Wire
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
ROCKVILLE, Md. & EDMONTON, Alberta, May 02, 2024--AURINIA PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATIONAL RESULTS
- Business Wire
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
ROCKVILLE, Md. & EDMONTON, Alberta, May 01, 2024--In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced several initiatives to improve understanding of the seriousness of lupus nephritis (LN) and the need for frequent screening and appropriate management, including an innovative disease state education campaign for rheumatologists.
© 2024 Yahoo. All rights reserved.